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Discussion

Research Question
How can molecular models be used to simulate the binding of various
HIV-1 protease inhibitors including Darunavir, Ritonavir, and a novel
combination of these two named “Sharkavir”?

Introduction
HIV has infected approximately 37 million people worldwide and
results in over 1 million deaths annually. A key component of the HIV
life cycle is the enzyme HIV-1 protease, which is involved in cutting
newly made protein components of the HIV virion (NIH, 2020). One of
the primary forms of treatment for HIV is to inhibit its protease through
a variety of competitive inhibitors; however, multiple mutations in HIV1 protease have caused these inhibitors to be less effective (Figure 1).
We collaborated with the CREST (Connecting Researchers,
Educators and STudents) Program of the Center for Biomolecular
Modeling (CBM) to depict this process (Herman et al., 2006; Procko et
al., 2019). Our CREST Team prepared a molecular model explaining
HIV-1 protease (Figure 2) and two of its potent inhibitors Darunavir
(DRV) and Ritonavir (RIT), which are both aspartic proteases that
result in peptide cleavage (Figure 3). DRV and RIT are being
prescribed as a mixed dose of both drugs as they are shown to be
more effective in combination than by administering one of these
drugs alone (Mehta et al., 2019). Inspired by this, we designed a
hybrid of these two inhibitors, which we named “Sharkavir”, and used
our molecular model to show how this inhibitor would bind to HIV-1
protease. The active site of HIV-1 protease (Surleraux et al., 2005)
was depicted as a binding box model. The protease inhibitors DRV
(Mittal et al., 2012), RIT (Prabu-Jeyabala, et al., 2003), and Sharkavir
were 3-D printed to show how they fit into the protease active site.

Figure 2: HIV-1 protease showing common
mutations in drug resistance – catalytic triad
circled in orange; key mutations circled in
Figure 1: HIV Lifecycle; green to correspond with Figures 5a and b
role of HIV-1 protease
(taken from Mittal et al., 2012).
(taken from NIH, 2020).

Methods

Three protein database files were used to create the molecular models
(Berman et al., 2000). These files were 1T3R (HIV-1 Protease), 4DQF
(Darunavir) and 1N49 (Ritonavir), Importing these files into Jmol, a
protein visualization software, allowed us to manipulate the crystal
structures of HIV-1 protease and these inhibitors. The hypothetical
drug Sharkavir was created as a molecular combination of DAR and
RIT using the program Marvin Sketch. The program AutoDock Vina
was used to model the binding of Sharkavir to HIV-1 protease (Morris
et al., 2009).

Figure 3: Mechanism of action of peptide cleavage by aspartic proteases including HIV1 protease (taken from Mahajan and Badgujar, 2010). The interactive hydroxide on the
inhibitor is highlighted in green with an asterix to correspond to Figure 4.

The development of Sharkavir was based on structures of established
inhibitors (DRV and RIT) and can be used as a model towards the insilico development of inhibitory molecules for a wide variety of enzymes.
Sharkavir maintains the benzyl ring that is sensed by the specificity
pocket consisting of Ile 84, Ile 50 and Val 82. The hydroxide that mimics
the tetrahedral intermediate of the substrate fits between the catalytic Asp
25 residues at the dimerization interface. Using the chemical hallmarks
present in known inhibitory molecules, combinatory drugs can be
modeled, and subsequently synthesized for targeted drug testing. Future
steps for this project could involve synthesizing the molecule in the
laboratory for inhibitor testing and crystallographic studies. The molecular
modeling techniques described are accessible to students and
researchers from a wide range of STEM fields and is a scientifically viable
first step in the long and costly drug design process. As more
undergraduate students are thinking about biochemical research concepts
and powerful computational tools become ubiquitous, this style of project
is very promising for research labs and as part of Course-Based
Undergraduate Research Experiences (CUREs).

Applications
3-D Molecular Models:
Figure 4: Ritonavir, Darunavir and Sharkavir
models prepared in spacefill using light CPK
(standard colors). Hydroxides are marked
with a green asterix.

Figure 5a: HIV-1 protease (1T3R)
manipulated in Jmol to show key amino
acids relevant in substrate binding.

.jpg

Figure 6. Sharkavir (blue) docked into the
active site of HIV-1 protease (1T3R) using
AutoDock Vina. Catalytic Asp 25 residues
are highlighted in red.

Figure 5b: HIV-1 protease (1T3R ) 3-D
printed as a 3-D printed protein binding
box model with key amino acids labeled.

Results - Model Information

Protease Inhibitors (Figure 4): Darunavir, Ritonavir, and “Sharkavir” (a molecular
combination of Darunavir and Ritonavir) were prepared in spacefill mode with light cpk
(standard chemical element colors) to show their binding to the active site box model.
The hydroxides that interact with the Asp 25 residues in the catalytic triad as part of the
aspartic protease mechanism were noted with a green asterix.
HIV-1 Protease Active Site Binding Box (Figures 5a and b):
• Two homodimers of HIV-1 protease shown in light yellow (lemonchiffon) and tan
• Catalytic triad containing Asp 25, Thr 26, and Gly 27 colored orange/salmon
• Five key amino acids in the active site that often mutate, leading to less specific
binding with their substrate inhibitors: Asp 30, Gly 48, Ile 50, Val 82, and Ile 84;
shown in standard cpk colors
• Sharkavir bound to HIV-1 protease along with catalytic Asp 25 residues (Figure 6)
• Each 3-D printed inhibitor can be manipulated to fit into the HIV-1 protease binding
box model.

• Visually represent molecular processes assisting in health and
student education
• Communicate ideas to others in the scientific community
• Assist in the development of novel drugs that can serve as enzyme
inhibitors
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